Company Overview of Neurotech Pharmaceuticals, Inc.
Neurotech Pharmaceuticals, Inc., a biotechnology company, engages in the development of transformative therapies for chronic eye diseases. Its products are based on encapsulated cell therapy (ECT), which is a genetically engineered ocular implant that enables continuous production of therapeutic proteins to the eye for a period of two years. The company offers NT-503 ECT, which is intended for use in the treatment of neo-vascular age-related macular degeneration; NT-506 ECT, which delivers anti-platelet-derived and anti-vascular endothelial growth factor proteins in a single implant; and NT-501 ECT, which is intended for use in treatment of retinal degenerative diseases. Neurotech Pharmaceut...
900 Highland Corporate Drive
Cumberland, RI 02864
Founded in 1995
Key Executives for Neurotech Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Vice President
Vice President of Core Technology Development
Compensation as of Fiscal Year 2015.
Neurotech Pharmaceuticals, Inc. Key Developments
Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study
Sep 2 15
Neurotech Pharmaceuticals, Inc. announced the first patient has been enrolled in the multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of recurrent subfoveal choroidal neovascularization secondary to age related macular degeneration (wet AMD). NT-503 is a unique vascular endothelial growth factor (VEGF) receptor protein continuously produced by Neurotech's versatile ECT implant. The Phase 2 randomized, active-controlled, masked study will evaluate the safety and efficacy of NT-503 ECT compared to aflibercept (Eylea®) intravitreal injections. Approximately 150 patients who have previously been treated with at least 3 anti-VEGF injections and have demonstrated a good clinical response will be enrolled. This study will compare maintenance of vision in patients randomized to receive a single NT-503 ECT implant or aflibercept injections every 8 weeks.Â Efficacy will be evaluated using a combination of endpoints including: change in visual acuity, change in retinal thickness, rate of treatment failures, and rate of rescue medication. A primary analysis will be conducted at one year and patients will be followed for two years.
Neurotech Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application and Clinical Trial Initiation of Novel Therapy for Wet Amd
Mar 30 15
Neurotech Pharmaceuticals, Inc. accepted and communicated Neurotech's ability to proceed with it's Investigational New Drug (IND) application to conduct a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of recurrent subfoveal choroidal neovascularization secondary to age related macular degeneration (wet AMD). The Phase 2, randomized, active-controlled, masked study will commence immediately and enroll 150 patients. The safety and efficacy of one NT-503 ECT implant will be compared to aflibercept intravitreal injections every 8 weeks in patients who have been treated with at least 3 anti-VEGF injections and still have active disease. Patients will be followed for 2 years with a 12-month interim assessment.
Neurotech Pharmaceuticals, Inc. Appoints Charles A Johnson, MD, as Chief Medical Officer
Mar 18 15
Neurotech Pharmaceuticals, Inc. announced that Charles A Johnson, MD, has assumed the role of Chief Medical Officer. Dr. Johnson is an accomplished physician and pharmaceutical executive with over four decades of experience in clinical practice and the biotech sector. Dr. Johnson was most recently the Vice President of Global Medical Affairs at Vertex.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|